Holder Ecor1 Capital LLC Has Boosted Xencor Ord (XNCR) Stake

Investors sentiment decreased to 1.5 in 2019 Q2. Its down 0.01, from 1.51 in 2019Q1. It is negative, as 8 investors sold XNCR shares while 32 reduced holdings. 18 funds opened positions while 42 raised stakes. 46.43 million shares or 0.38% less from 46.61 million shares in 2019Q1 were reported. Rhumbline Advisers reported 82,314 shares. Tocqueville Asset Management Lp reported 8,100 shares. Bancorp Of Montreal Can reported 3,980 shares. Primecap Management Ca holds 0.23% of its portfolio in Xencor, Inc. (NASDAQ:XNCR) for 7.45 million shares. Oregon Employees Retirement Fund owns 10,000 shares. First Light Asset Lc reported 499,344 shares or 2.84% of all its holdings. Proshare Advsrs has invested 0.01% in Xencor, Inc. (NASDAQ:XNCR). Deutsche State Bank Ag holds 26,950 shares. United Kingdom-based Barclays Public Ltd Company has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Vident Inv Advisory Lc invested in 44,733 shares or 0.15% of the stock. Citadel Advsr Ltd Liability Corp has 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 43,916 shares. Gsa Cap Ptnrs Ltd Liability Partnership stated it has 0.08% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Bankshares Of America De holds 0% or 50,607 shares. Citigroup accumulated 30,283 shares or 0% of the stock.

Since March 15, 2019, it had 3 buys, and 0 selling transactions for $978,109 activity.

Ecor1 Capital Llc increased its stake in Xencor Ord (XNCR) by 13.46% based on its latest 2019Q2 regulatory filing with the SEC. Ecor1 Capital Llc bought 277,128 shares as the company’s stock rose 46.93% . The institutional investor held 2.34M shares of the health care company at the end of 2019Q2, valued at $95.64M, up from 2.06 million at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Xencor Ord for a number of months, seems to be bullish on the $1.96 billion market cap company. The stock decreased 0.28% or $0.1 during the last trading session, reaching $35.38. About 238,638 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 23.34% since September 13, 2018 and is uptrending. It has outperformed by 23.34% the S&P500.

Ecor1 Capital Llc, which manages about $989.64M US Long portfolio, decreased its stake in Crispr Therapeutics Ord by 268,027 shares to 1.61M shares, valued at $75.84M in 2019Q2, according to the filing. It also reduced its holding in Assembly Biosciences Ord (Call) (NASDAQ:ASMB) by 655,299 shares in the quarter, leaving it with 498,300 shares, and cut its stake in Mersana Therapeutics Ord.

Another recent and important Xencor, Inc. (NASDAQ:XNCR) news was published by Finance.Yahoo.com which published an article titled: “Here’s What Hedge Funds Think About Xencor Inc (XNCR) – Yahoo Finance” on June 24, 2019.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Among 3 analysts covering Xencor Inc (NASDAQ:XNCR), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Xencor Inc has $5200 highest and $21 lowest target. $40’s average target is 13.06% above currents $35.38 stock price. Xencor Inc had 9 analyst reports since March 14, 2019 according to SRatingsIntel. The rating was initiated by Raymond James with “Buy” on Thursday, March 14. Canaccord Genuity maintained Xencor, Inc. (NASDAQ:XNCR) on Thursday, August 8 with “Buy” rating. Nomura maintained it with “Sell” rating and $21 target in Thursday, March 21 report.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.